BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• 

  Job Trends

  BioSpace Reveals Fresh Design With 2026 Hotbed Maps, Highlighting Life Sciences Hubs

  BioSpace has revealed its new 2026 Hotbed Maps, showcasing seven regional life sciences hot spots.

  January 20, 2026

   · 

  2 min read

   · 

  Chantal Dresner
• 

  Vaccines

  Pfizer Makes $530M Vaccine Play With Novavax Deal After Rumors of BioNTech Pullback

  In November, Pfizer was reportedly looking to divest its stake in BioNTech, though the German biotech at the time denied these rumors.

  January 20, 2026

   · 

  1 min read

   · 

  Tristan Manalac
• 

  CAR-T

  AstraZeneca Pays $630M for Complete Global Rights Over AbelZeta’s CAR T

  The arrangement will boost AstraZeneca’s cell therapy portfolio as the pharma targets $80 billion in revenue by 2030.

  January 20, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Mergers & acquisitions

  GSK Picks Up RAPT for $2.2B as Miels Makes First Move as CEO

  The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, potentially setting up a competition for GSK with Roche’s Xolair.

  January 20, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Manufacturing

  CDMOs Pin Hopes for Accelerating Uptake at New US Sites on FDA’s PreCheck Program

  The initiative could tackle the first-mover disadvantage some CDMOs believe deters early customers, but leaders at companies including Novo Nordisk see hurdles to implementing the changes.

  January 20, 2026

   · 

  4 min read

   · 

  Nick Paul Taylor
• 

  Cancer

  Moderna, Merck Show Long-Term Survival for mRNA-Keytruda Combo

  The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with immuno-oncology heavyweight Keytruda.

  January 20, 2026

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Obesity

  JPM26: After a Tough 2025, Biohaven Is Gearing Up To Challenge Goliath—Lilly

  Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.

  January 20, 2026

   · 

  3 min read

   · 

  Dan Samorodnitsky
• Press Releases

  Bavarian Nordic – Transactions in Connection with Share Buy-Back Program - January 19, 2026

  January 20, 2026

   · 

  2 min read
• Press Releases

  Valneva Provides Update on Chikungunya Vaccine IXCHIQ®

  January 20, 2026

   · 

  6 min read
• Press Releases

  Alcami Acquires RTP Facility to Further Expand Biologic Capabilities

  January 20, 2026

   · 

  2 min read